ArticleJournal of robotic surgery2026
Predictors of persistent PSA after robot-assisted radical prostatectomy: a high-volume single-center experience.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate clinical and pathological factors associated with persistent prostate-specific antigen (pPSA) after robot-assisted radical prostatectomy (RARP). This retrospective study included 1,066 patients who underwent RARP between June 2019 and February 2022. Patients were grouped according to postoperative PSA as persistent (≥ 0.1 ng/mL at 4–8 weeks) or undetectable. Clinical and pathological variables were compared, and univariable and multivariable logistic regression analyses were performed to identify independent predictors of pPSA. Persistent PSA was observed in 193 of 1,066 patients (18.1%). Patients with pPSA had significantly higher preoperative PSA levels (12.9 vs. 7.1 ng/mL; p < 0.001), higher biopsy positivity rates and higher International Society of Urological Pathology (ISUP) grades, more advanced clinical and pathological stages, and were more frequently classified as high risk according to the D’Amico system (all p < 0.001). Patients with pPSA more frequently underwent pelvic lymph node dissection and less frequently received bilateral nerve-sparing surgery. Persistent PSA was significantly associated with multiple adverse pathological features, including intraductal carcinoma, lymphovascular invasion, extraprostatic extension, perineural invasion, seminal vesicle invasion, positive surgical margins, advanced pathological stage, nodal involvement, and higher tumor burden (all p < 0.05). In multivariable analysis, preoperative PSA level, seminal vesicle invasion, positive surgical margins, presence of intraductal carcinoma, and postoperative ISUP grade ≥ 4 were identified as independent predictors of pPSA. ROC analysis identified an optimal preoperative PSA cut-off value of 10.0 ng/mL for predicting pPSA, with an AUC of 0.736, sensitivity of 62.7%, and specificity of 73.3%. Persistent PSA may reflect more aggressive tumor biology and can be independently predicted using routinely available clinical and pathological parameters. Early identification of high-risk patients may facilitate individualized follow-up and timely planning of adjuvant or salvage treatment strategies.
Indexed as
Identifiers
41872615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.